Skip to content
Back to meeting Original
Abdulaziz AlJassim· @DrZ_84 · X·· 4 days agoScore70

lorlatinib

Body

Proud to share our long-term real-world experience with lorlatinib in ALK+ NSCLC from Kuwait Cancer Control Center at #ESMO2026

Single-Center Retrospective cohort (N=26):
ORR: 83%
DCR: 96%
Longest ongoing exposure: >85 months

#LCSM #ALK

91 views · 1 like · 0 reposts · 0 replies

Conference abstracts
2636ROmatched by Rapid oral 1: NSCLC, metastatic

Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study

https://esmocongress.esmo.org

Source: Abdulaziz AlJassim · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.